Sonova Holding AG (PHBA) AI Stock Analysis

Sonova Holding AG

(Frankfurt:PHBA)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Product-led hearing instruments growthStrong hearing-instrument and wholesale growth indicates sustained adoption of Sonova’s products and successful market-share gains. New launches such as Infinio Ultra and Virto R can support repeat upgrades, premium mix, and continued competitive momentum over the next several quarters.

Negative Factors

Cochlear implant weakness and China pressureThe cochlear-implant business is facing both regulatory pricing pressure in China and heightened competition, which has reduced system and upgrade volumes. Its low 6.8% normalized EBITDA margin makes prolonged weakness a meaningful drag on group growth and profitability until recovery efforts take hold.

Sonova Holding AG (PHBA) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 20.42B
Dividend Yield: 1.65%
Average Volume (3M): 18
Price to Earnings (P/E): 39.4
Beta (1Y): 0.87
Revenue Growth: -4.58%
EPS Growth: -18.57%
Country: Germany
Employees: 18,447
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Sonova Holding AG Business Overview & Revenue Model

Company Description

Sonova Holding AG is a prominent developer, manufacturer, and global distributor of hearing health solutions for all age groups. The company's operations are divided into two core areas: Hearing Instruments and Cochlear Implants. Its product range in...

Sonova Holding AG Earnings Call Summary

Earnings Call Date:May 17, 2026(Q4-2026)|% Change Since:63.13%|Next Earnings Date:Nov 11, 2026

Earnings Call SentimentPositive

The call highlights strong product-led sales momentum (notably in wholesale and select APAC markets), meaningful operating leverage, high cash conversion and disciplined capital allocation. Key short-term challenges are concentrated in the Cochlear Implants business (notably China) and several non‑core one-off charges plus FX headwinds. Management provided a confident but execution‑sensitive midterm roadmap (innovation, multi-channel expansion, operational savings) and reiterated growth and margin guidance for FY26/27.

Positive Updates

Strong Hearing Instruments Growth and Margin Expansion

Hearing Instruments segment sales rose 7.5% to CHF 3.4bn with growth accelerating to 7.9% in H2. Normalized EBITDA for the segment increased 17.3% to CHF 794m, delivering a 23.7% margin (up ~280 basis points in local currencies).

Negative Updates

Cochlear Implants Sales and Profit Pressure

Cochlear Implants sales declined 11% to CHF 252m (or -3.8% excluding China). System sales fell ~10% and upgrade sales declined 13%. Normalized EBITDA for CI was CHF 17.2m (margin ~6.8%), materially impacted by lower volumes and competitive pressure.

Company Guidance

Sonova guided FY 2026/27 to consolidated sales growth of 5–8% and core EBIT growth of 7–10% at constant exchange rates, assuming market growth of about 2–4% this year (trending toward a mid‑term 3–5% range); they expect wholesale to outpace the market, retail to deliver robust organic growth plus ~1–2% contribution from M&A and accelerated store openings, and Cochlear Implants to face H1 headwinds with a meaningful H2 pickup after a planned new processor launch. Management flagged modelling items: non‑core items of CHF 35–40m, M&A contribution to group sales ~1–2%, and FX as of early May 2026 that would reduce reported Swiss‑franc sales growth by ~1–2 percentage points and core EBIT growth in CHF by ~2–3 percentage points; H1 is expected to lie within the 7–10% core EBIT growth range.

Sonova Holding AG Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:PHBA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDT	74Outperform	$123.49B	24.28	10.60%	2.88%	9.77%	12.28%
INSP	72Outperform	$1.97B	19.31	17.62%	―	4.35%	161.83%
ABT	69Neutral	$183.77B	40.80	9.12%	2.29%	10.00%	―
LIVN	69Neutral	$4.35B	23.25	15.41%	―	12.39%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
COCH	44Neutral	$51.31M	-0.99	1719.71%	―	-6.76%	42.70%

* Healthcare Sector Average

Performance Comparison

DE:PHBA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:PHBA	Sonova Holding Ag Unsponsored Adr	59.50	15.53	35.33%
ABT	Abbott Laboratories	110.16	-12.59	-10.26%
MDT	Medtronic	99.29	11.77	13.45%
LIVN	LivaNova PLC	80.21	26.27	48.70%
INSP	Inspire Medical	67.21	-17.80	-20.94%
COCH	Envoy Medical, Inc. Class A	6.65	-0.60	-8.30%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Sonova Holding AG AI Stock Analysis